Shiga-like toxin II derived from Escherichia coli O157:H7 modifies renal handling of levofloxacin in rats

Antimicrob Agents Chemother. 2002 May;46(5):1522-8. doi: 10.1128/AAC.46.5.1522-1528.2002.

Abstract

The effect of Shiga-like toxin II (SLT-II) (2 microg/animal), which was derived from Escherichia coli O157:H7, on renal handling of levofloxacin (LVX), a model drug for quinolone antimicrobial agents, was investigated in rats 24 h after intravenous injection. In histopathological examination, acute tubular injury was observed in SLT-II-treated rats, but the glomeruli were not injured. SLT-II significantly increased the steady-state concentration of LVX in plasma to 1.5-fold that of control rats. SLT-II induced significant decreases in the glomerular filtration rate (GFR) and renal clearance (CL(R)) of LVX. SLT-II slightly, but significantly, increased the unbound fraction and decreased renal plasma flow with no change in the extraction ratio of p-aminohippurate. SLT-II significantly increased concentrations of tumor necrosis factor alpha (TNF-alpha) and nitrite and nitrate (NOx) in plasma. The TNF-alpha inhibitor pentoxifylline partly, but significantly, inhibited SLT-II-induced decreases in the GFR and CL(R) of LVX; in contrast, S-methylisothiourea, a selective inhibitor of inducible nitric oxide synthase, did not. Western blotting analysis revealed that SLT-II did not alter the levels of multidrug resistance-associated protein 2 (Mrp2) and P-glycoprotein in kidneys 24 h after injection, assuming the lack of involvement of Mrp2 and P-glycoprotein in SLT-II-induced acute renal tubular injury and renal handling of LVX observed 24 h after SLT-II injection. The present study suggests that SLT-II impairs the renal handling of LVX by decreasing GFR and causing decreased renal plasma flow.

MeSH terms

  • ATP Binding Cassette Transporter, Subfamily B, Member 1 / metabolism
  • ATP-Binding Cassette Transporters*
  • Animals
  • Anti-Infective Agents / pharmacokinetics*
  • Anti-Infective Agents / urine
  • Carrier Proteins / metabolism
  • Escherichia coli O157 / metabolism*
  • Glomerular Filtration Rate / drug effects
  • Humans
  • Kidney / drug effects
  • Kidney / metabolism*
  • Levofloxacin*
  • Male
  • Metabolic Clearance Rate / drug effects
  • Ofloxacin / administration & dosage
  • Ofloxacin / pharmacokinetics*
  • Ofloxacin / urine
  • Rats
  • Rats, Wistar
  • Shiga Toxin 2 / metabolism
  • Shiga Toxin 2 / pharmacology*

Substances

  • ATP Binding Cassette Transporter, Subfamily B, Member 1
  • ATP-Binding Cassette Transporters
  • Abcc2 protein, rat
  • Anti-Infective Agents
  • Carrier Proteins
  • Shiga Toxin 2
  • Levofloxacin
  • Ofloxacin